Tagged with Investment

India Dr Viranchi Shah of Saga Lifesciences and the Indian Drug Manufacturers Association (IDMA) outlines the Indian pharmaceutical industry’s potential for growth and its role in global health initiatives. He highlights IDMA’s focus on scaling operations, affordability, accessibility, quality, and compliance to drive positive change across the sector. Dr Shah also…

Saudi Arabia Dr Dalia Samra-Rothe highlights the role of AHK in facilitating German companies’ entry into the Saudi market, the significant economic transformation and opportunities in Saudi Arabia, and the importance of cultural awareness and preparedness when doing business in the country.   [Saudi Arabia] is undergoing a truly remarkable transformation, unlike…

India Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation. Now though, as India’s GDP and market value soar and the policy environment shifts towards prioritising the domestic development of…

India The State of Gujarat is one of India’s most culturally diverse, the birthplace of ‘Father of the Nation’ Mahatma Gandhi, and the only place in the world where Asiatic lions can be found in their natural habitat. It is also an economic powerhouse, with key Gujarati industries including dairy, cement,…

Saudi Arabia As the GCC’s largest market, Saudi Arabia, with its growing population, strong healthcare infrastructure and government commitment to developing the economy beyond oil through its Vision 2030, is increasingly attractive for multinational pharma and local players alike. In 2024 government reforms will continue to encourage investment and local production while…

India Dr Arunish Chawla details the policy strategies underlying the explosive prospected growth of India’s pharmaceutical sector to USD 120-150 billion by 2030, including rigorous adherence to international quality standards. Highlighting regulatory reforms and India’s nuanced stance on intellectual property, Dr Chawla envisions India as a balanced player in healthcare across…

India At a transformational moment for Indian pharma, OPPI’s Anil Matai outlines how the country’s government is more receptive to innovation and action-oriented than ever before, how the industry is increasingly aligning with global standards to foster an innovation transition, and the importance of always bearing patiennt accessibility in mind in…

India Pharmexcil’s Ravi Uday Bhaskar discusses how Indian pharma is rebuilding global confidence in its exports via a focus on quality, expanding into high-potential new markets like those in Latin America, and adapting to global trends like the US Inflation Reduction Act and changing European regulations.   Despite global economic challenges,…

Portugal Joana Branco of Biocant Park, Portugal’s pioneering biotech hub, delves into its strategic development and international impact since 2005. Branco highlights Biocant’s role in advancing the Portuguese life sciences sector, attracting around 43 companies with its state-of-the-art infrastructure and a collaborative ecosystem. Despite challenges such as Portugal’s size and the…

India The Bombay Chamber of Commerce, established in 1836, played a key role in India’s industrial and infrastructural development during British rule and has since evolved into a professional organization with influential members, contributing significantly to the growth of major international companies like Tata and Reliance. Director General Sandeep Khosla highlights…

USA Cardiff Advisory’s David H. Crean outlines the positive atmosphere and sentiment observed at JPM 2024, the annual healthcare financing conference held near San Francisco’s Union Square. Dr. Crean picks up some of the key trends to emerge from the conference around sustainability, deal flow, venture funding, and AI, and provides…

Hong Kong Hong Kong Exchanges and Clearing Limited (HKEX) chief executive Nicolas Aguzin has stepped down after a term fraught with upheaval. Having survived COVID-19 isolation, under Aguzin HKEX was confronted with strict regulatory crackdowns and has seen a drop in funds raised from initial public offerings by almost 40 percent. Newly…